Cannabidiol (CBD) Oral Solution 300 mg/day for Phobia, Social

Phase-Based Progress Estimates
Phobia, Social+2 More
Cannabidiol oral solution - Drug
All Sexes
What conditions do you have?

Study Summary

A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).

Eligible Conditions
  • Phobia, Social

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 10 weeks

10 weeks

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

3 Treatment Groups

Cannabidiol (CBD) Oral Solution 300 mg/day
1 of 3
Cannabidiol (CBD) Oral Solution 600 mg/day
1 of 3
Placebo Oral Solution
1 of 3

Experimental Treatment

Non-Treatment Group

225 Total Participants · 3 Treatment Groups

Primary Treatment: Cannabidiol (CBD) Oral Solution 300 mg/day · Has Placebo Group · Phase 2

Cannabidiol (CBD) Oral Solution 300 mg/day
Experimental Group · 1 Intervention: Cannabidiol oral solution · Intervention Types: Drug
Cannabidiol (CBD) Oral Solution 600 mg/day
Experimental Group · 1 Intervention: Cannabidiol oral solution · Intervention Types: Drug
Placebo Oral Solution
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 10 weeks

Who is running the clinical trial?

EmpowerPharm Inc.Lead Sponsor

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a clinically predominant diagnosis of SAD.
You have a score of 70 or higher on the LSAT.
You have no significant physical health abnormalities based on physical exam, ECG and laboratory tests.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 7th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Met criteria100.0%
Why did patients apply to this trial?
  • "It might help me"
What questions have other patients asked about this trial?
  • "Can I participate from worldwide?"
How many prior treatments have patients received?